Xenogen — Merger or Acquisition (February 2006)
9 slides from Xenogen's merger presentation, Feb 16, 2006

Slide 1: Transforming Discovery with Innovative Technologies
Transforming Discovery with Innovative Technologies February 14, 2005 Happy Valentines Day!

Slide 2: Discovery Value Chain
Relevance—=>>——» Discovery Value Chain SS In Vitro Y¥ ole. +Fluidics & Automation *Biophotonics Detection Detection +Assays: +Molecular Biology *Biochemistry + Services +Services W Caliper...

Slide 3: Overall strategic, structural and financial fit assessment
inwaorevanee a re ace eT TNT Imaging relevance ‘3 The Ceacpicn a Taneen ear acbp nelaeun Propeey + andl Po chinese ig Patel pptcalons bona * a See, a LE ESN RTS SORT PATER Atocve Teng ColpersTaI0G BOE + enimodrineraet cnemar aa ‘Seng atrmarel polenta + Poa obi Sc anu am aA Serves average * TS STE DU

Slide 4: Significant upside potential exists in several areas
igniticant upside potential exists In seve! areas LPTA and ZebBio technology combined, Caliper product ZebraBio and NovaScreen Services technology Applications strategy : Accounts J Revenues per account YW Caliper,

Slide 5: Caliper Status
Caliper Status > Revitalized financials with a revitalized strategy / momentum » Solid management and operational team with capacity / desire for growth > Strong market reach into Pharma and Biotech with track record for commercializing transformative technologies into profitable and sustainable pro

Slide 6: Opportunity: Merge C and Z
Opportunity: Merge C and Z > Through unique senior level Pharma/Biotech relationships, we have identified a keen emerging interest in Biomarker research and Imaging technologies. > Today, C has a minimal, but emerging position in Biomarker research, but lacks a position in the rapidly expanding imag

Slide 7: Opportunity: Merge C and Z - Continued
tinued pportunity: Merge C and Z - C » A carefulprocess has resulted in a unique opportunity to merge Z and C now. Transaction economics are compelling to both sets of owners. » C has the demonstrated experience and capabilities to integrate Z and, based on the diligence learnings, is confident of s

Slide 8: C & Z Merger Catalyzes Our Strategy
C & Z Merger Catalyzes Our Strategy M&A screens have yielded a small number of actionable opportunities » Filter: Strategic fit, cost synergies, under valued, insufficient critical mass >» Z Merger: Super charges top line growth on larger base Breakthrough critical mass valuation Improves trajectory

Slide 9: Value drivers for life sciences companies are improved by joining forces
Value drivers for life sciences companies are improved by joining forces ie) ic) ° ° eo) ° ° 3 e @ ° Qo i) ° Grn | © © e ‘YW caliper.
Source: SEC EDGAR · DEFA14A filed Feb 16, 2006

